Upload
scarlett-atkinson
View
224
Download
0
Tags:
Embed Size (px)
Citation preview
DYSLIPIDEMIAS:TYPES I-V
Thomas F. Whayne, Jr, MD, PhD, FACC
Professor of Medicine (Cardiology)
University of Kentucky
March 2011.
E-Mail: [email protected].
No conflicts to declare.
THE MAJOR LIPOPROTEINS
• CHYLOMICRONS.• VERY LOW DENS. LIPOPROT. (VLDL). • LOW DENS. LIPOPROT. (LDL) .• HIGH DENS. LIPOPROT. (HDL) .
NormalType
IType IIA
Type IIB
Type III
Type IV
Type V
Before UC After UC
Tube Plain
VLDL
LDL
HDL
Tube with KB
VLDL
LDL
HDL
TYPE I
• RARE GENETIC DISORDER.
• HYPERCHYLOMICRONEMIA.
• LIPOPROTEIN LIPASE DEFICIENCY.
TYPE I: TREATMENT
• RESTRICTION OF FATS.
• PANCREATITIS: NPO.
• MEDIUM CHAIN FATTY ACID TRIGLYCERIDES.
TYPE II-A HYPERLIPOPROTEINEMIA
AUTOSOMAL DOMINANT.– HETEROZYGOTES: 1 IN 500.– HOMOZYGOTES: 1 IN 1,000,000.
TYPE II-A IS ALSO:
• POLYGENIC.
• SPORADIC.
• POSSIBLY ACQUIRED
TYPE II-A
• ACCELERATED ATHEROSCLEROSIS, ESPECIALLY CORONARY.
• TENDON XANTHOMAS.
• TUBEROUS XANTHOMAS.
• XANTHELASMA.
• CORNEAL ARCUS.
EXTREME EXAMPLE OF TYPE II-A HYPERLIPOPROTEINEMIA
STORMY JONES: AGE 10.
TYPE II-B
ACCELERATED ATHEROSCLEROSIS: CORONARY AND PERIPHERAL
TYPES IIA/IIB: TREATMENT
• STATINS ESPECIALLY.
• BILE ACID BINDING RESINS, ESPECIALLY COLESEVELAM.
• NICOTINIC ACID (NIASPAN®).
• ZETIA.
• POLICOSANOL.
• LDL APHERESIS.
TYPE III
• ACCELERATED ATHEROSCLEROSIS, ESPECIALLY PERIPHERAL.
• PALMAR XANTHOMAS.
• TUBEROUS XANTHOMAS.
TYPE III
APO E IN LIVER RECEPTORS IS ABNORMAL OR DEFICIENT FOR:– LOW DENS. LIPOPROTEINS (LDL).– INTERMED. DENS. LIPOPROTEINS (IDL).– CHYLOMICRON REMNANTS.
TYPE III TREATMENT
• LOW CHOLESTEROL UNSATURATED FAT DIET.
• SOME CARBOHYDRATE (SIMPLE SUGARS) RESTRICTION.
• CLOFIBRATE (ATROMID).• GEMFIBROZIL (LOPID).• FENOFIBRATE (TRICOR).• STATIN.
TYPE IV HYPERLIPOPROTEINEMIA
• ALSO CALLED FAMILIAL HYPERTRIGLYCERIDEMIA.
• ACCELERATED ATHEROSCLEROSIS, ESPECIALLY PERIPHERAL.
TYPE IV: TREATMENT
• FENOFIBRATE.• NICOTINIC ACID (NIASPAN®).• OMEGA FATTY ACIDS (LOVAZA®).• METFORMIN.• PIOGLITAZONE.• STATINS.• EZETIMIBE.• INSULIN.
TYPE V
• INCREASED CHYLOMICRONS AND VLDL.
• CAN BE RARE GENETIC DISORDER.
• CAN BE MORE FREQUENTLY SEEN IN DIABETES, EVEN WITH MILD INCREASE IN PLASMA GLUCOSE.
TYPE V: TREATMENT
• CONTROL DIABETES.
• FENOFIBRATE.
• NICOTINIC ACID (NIASPAN®).
• OMEGA FATTY ACIDS (LOVAZA®).
• METFORMIN.
• PIOGLITAZONE.
• INSULIN.
DYSLILPIDEMIA IN DIABETES:TYPICAL PATTERN
• HIGH LEVELS OF TRIGLYCERIDES.
• LOW LEVELS OF HDL.
• PREPONDERANCE OF SMALL DENSE LDL.
SMALL, DENSE LDL
• ASSOCIATED WITH 3X RISK OF CHD.
• INCREASED ATHEROGENICITY:– FASTER ENTRY INTO BLD. VESSEL WALL. BINDING TO LDL RECEPTOR.– INCREASED SUSCEPTIBILITY TO
OXIDATION.
TRIGLYCERIDES IN DIABETES
• HIGH TRIGLYCERIDE LEVELS OCCUR MAINLY IN VLDL BUT ALSO IN CHYLOMICRONS.
• ELEVATED TRIGLYCERIDE LEVELS RESULT FROM:– OVERPRODUCTION OF VLDL.– IMPAIRED LIPOLYSIS OF
TRIGLYCERIDES (INSULIN IS AN LPL COFACTOR).
ADA RATIONALE FOR Rx OF DYSLIPIDEMIA IN DIABETES
• THERE IS RISK OF CHD BECAUSE OF DYSLIPIDEMIA.
• DIABETIC DYSLIPIDEMIA FREQUENTLY CHARACTERIZED BY TRIGLYCERIDES, HDL AND SMALL, DENSE LDL.
• Rx OF DIABETIC DYSLIPIDEMIA MAY REDUCE RISK OF CHD.
IMPROVED CONTROL OF HYPERGLYCEMIA
• CAN REDUCE DYSLIPIDEMIA.
• MAY RESULT IN ATHEROGENIC DENSE LDL.
• COMPLETE REVERSAL OF DYSLIPIDEMIA USUALLY NOT ACHIEVABLE.
RESPONSE OF DENSE LDL TO MEDICATION
• FIBRATES AND NICOTINIC ACID (NIASPAN®) SHIFT THESE DENSE LDL TO A LARGER SIZE LDL PARTICLE.
• STATINS ARE NOT EFFECTIVE IN FAVORABLE SHIFT OF DENSE LDL TO LARGER, LESS DENSE LDL PARTICLE.
FIBRATES IN TYPE II DIABETICS
STUDY DRUG DIABETIC SUBJECTS
RESULTS:
DIABETES
HELSINKI HEART
GEMFI-BROZIL
135 (4081) 65% CARDIAC
EVENTS, NS
VA HIT GEMFI-BROZIL
627 (2531) 24% CAD DEATHS, MI AND CVA, < 0.05
DAIS FENOFI-BRATE
418(418) 23% CV EVENTS, DEATHS (PRELIM.)
Syndrome X, Metabolic Syndrome or Cardiovascular Dysmetabolic Syndrome
• Obesity.
• Hypertriglyceridemia.
• Low HDL.
• Increased Dense LDL.
• Hypertension.
• Insulin Resistance.
• Hyperuricemia.
• Increased PAI-1.
AT LEAST 3 OF THE FOLLOWING 5 PRESENT†:TG 150 mg/dl.HDL < 40 mg/dl in men and < 50 mg/dl in women .BP 130/85 mm/Hg.Waist girth > 102 cm (men) and > 88 cm (women).Fasting glucose 100 mg/dl.
OTHER COMPONENTS: dense LDL, Insulin resistance, Hyperuricemia, PAI-1, hsCRP, Tissue necrosis factor-α Interleukin-6, Resistin, and Adiponectin.
METABOLIC SYNDROME, SYNDROME X
or CV DYSMETABOLIC SYNDROME
†Grundy SM, et al. Circulation 2005;112:2735-2752.
Adapted from: Ford ES, et al. JAMA 2002;287:356-359.
47 million or 23% of US adults have the metabolic syndrome
Metabolic Syndrome: Prevalence Increases with Age
MARKED HYPERTRIGLYCERIDEMIA
CAN OCCUR FROM RETROVIRUS Rx IN HIV
PATIENTS
Thiazides:
• Marked elevation of triglycerides and VLDL can occur.
• Increased total cholesterol and LDL.
• Little effect on HDL.
ESTROGEN
SPORADICALLY AND UNPREDICTABLY, ESTROGEN MAY CAUSE A MARKED ELEVATION IN TRIGLYCERIDES.
BETA BLOCKERS
• Increase triglycerides and VLDL.
• Decrease HDL.
• Less significant increase in Total Cholesterol and LDL.
• Beta Blockers with ISA may have a less pronounced effect.
CONCLUSION
MULTIPLE APPROACHES AVAILABLE TO ACHIEVE GOOD BLOOD LIPID CONTROL AND THEREBY AVOID MULTIPLE CLINICAL PROBLEMS INCLUDING SEQUELAE OF CORONARY ATHEROSCLEROSIS.